Elanco announces organizational restructuring including 300 positions eliminated

Elanco (ELAN) will implement organizational changes designed to generate approximately $25M and $60M in savings in 2026 and 2027, respectively, as part of its Elanco Ascend productivity initiative. Elanco is expanding its R&D organization in Indianapolis, refining its regulatory structure and proposing the closure of its Germany animal facility. The company also announces a strategic partnership with The Clinglobal Group to substantially expand capacity and capabilities, while being significantly more cost effective. Elanco will continue to optimize its manufacturing footprint to power its pipeline, adjust to future volume expectations and continue the organization’s productivity journey, including reducing workforce in higher-cost locations. Approximately 600 roles will be impacted across Elanco with 300 eliminated positions and 300 shifted to other areas or locations. The company expects a charge of approximately $175M, of which about $130M is expected to be cash based.